FindTrial
Sign In

Role of Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI) in predicting Chemoradiation Sensitive Nasopharyngeal Carcinoma and Plasma Epstein-Barr virus (EBV) level

Role of Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI) in predicting Chemoradiation Sensitive Nasopharyngeal Carcinoma and Plasma Epstein-Barr virus (EBV) level

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20180227002
Enrollment
40
Registered
2018-02-27
Start date
2018-02-27
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasopharyngeal carcinoma Dynamic contrast enhanced magnetic resonance imaging Perfusion Nasopharyngeal carcinoma

Interventions

Patients with pathologically proven of NPC in King Chulalongkorn Memorial Hospital who will receive chemoradiation therapy as a primary treatment
Diagnostic
Nasopharyngeal carcinoma

Sponsors

none
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Newly diagnosed patients with pathologically proven of NPC in KCMH Receive chemoradiation therapy as a primary treatment Known pretreatment plasma EBV DNA level

Exclusion criteria

Exclusion criteria: Presence of metastasis Received primary treatment other than chemoradiation Previous chemoradiation therapy

Design outcomes

Primary

MeasureTime frame
Value of DCE-MRI in term of predicting chemoradiation sensitive nasopharyngeal carcinom 1 year DCE MRI parameters—

Secondary

MeasureTime frame
Value of DCE-MRI in term of predicting plasma EBV level in patient with nasopharyngeal carcinoma 1 year DCE MRI parameters—

Countries

Thailand

Contacts

Public ContactNutchawan Jittapiromsak

Chulalongkorn University

peanut_md@hotmail.com022564414

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026